Jpmorgan Chase & CO Oyster Point Pharma, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$7.95 - $11.68 $189,345 - $278,182	23,817 Added 1388.75%	25,532 $285,000
Q3 2022 Nov 14, 2022	BUY	$4.41 - $8.38 $3,170 - $6,025	719 Added 72.19%	1,715 $10,000
Q2 2022 Aug 11, 2022	SELL	$3.6 - $11.2 $26,236 - $81,625	-7,288 Reduced 87.98%	996 $4,000
Q1 2022 May 11, 2022	BUY	$8.58 - $17.65 $14,757 - $30,357	1,720 Added 26.2%	8,284 $97,000
Q4 2021 Feb 10, 2022	BUY	$10.17 - $18.96 $23,370 - $43,570	2,298 Added 53.87%	6,564 $120,000
Q3 2021 Nov 12, 2021	BUY	$11.67 - $18.07 $49,784 - $77,086	4,266 New	4,266 $51,000

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.